2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Danaher Corporation company profile · business segments · history · financial snapshot · S&P 500 rank #75 · 丹納赫公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | DHR |
| Company | Danaher Corporation |
| GICS sector / industry | Health Care (XLV) / Life Sciences Tools & Services |
| S&P 500 rank (by weight) | #75 · 0.24% (Oct 29, 2026) |
| Sector rank | #11 in Health Care (Oct 29, 2026) |
| Headquarters | Washington, D.C. |
| Founded | 1984 |
| CEO | Rainer M. Blair |
| Employees | Approximately 63,000 (Dec 31, 2024) |
| Market cap | $166.59B (Oct 30, 2026) |
| Share price | $232.23 (Oct 30, 2026 close) |
| SEC filings | EDGAR — CIK 0000313616 |
WHAT IT DOES
Danaher sells life-sciences tools, diagnostics and bioprocessing products used to discover, develop and manufacture drugs.
Its biotechnology segment, including Cytiva, supplies the filters, resins and systems biomanufacturers need.
Diagnostics, including Beckman Coulter and Cepheid, serves hospitals and laboratories.
BUSINESS SEGMENTS
| Biotechnology | Bioprocessing products for drug manufacturing, including Cytiva. FY2024 revenue $6,759M; operating income $1,685M. |
| Life Sciences | Instruments and consumables for research laboratories. FY2024 revenue $7,329M; operating income $879M. |
| Diagnostics | Clinical diagnostics including Beckman Coulter and Cepheid. FY2024 revenue $9,787M; operating income $2,625M. |
HISTORY
| Year | Milestone |
|---|---|
| 1984 | Steven and Mitchell Rales found Danaher. |
| 2016 | Danaher spins off its industrial businesses as Fortive. |
| 2020 | Danaher acquires Cytiva. |
| 2023 | Danaher spins off its environmental and applied solutions businesses as Veralto. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $24.57B (FY2025 sales) |
| Operating income | $4.69B (FY2025 operating profit) |
| Net income | $3.61B (FY2025 net earnings) |
| Diluted EPS | $5.05 (FY2025 diluted EPS from continuing operations) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Danaher is the picks-and-shovels play on drug development: it sells the tools every biomanufacturer needs, with the Danaher Business System driving margins. The risk is the biotech funding cycle, which swings demand for its highest-margin bioprocessing products.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | Danaher Corporation Form 10-K / 2024 annual report (sales $23.88B; operating profit $4.86B; net earnings $3.90B; diluted EPS $5.29 from continuing operations). |
| Index weight & ranks | Slickcharts S&P 500 weights, Oct 29, 2026 close, fetched Oct 30, 2026 |
| Market cap | $166.59B (Oct 30, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | DHR |
| 公司 | 丹納赫公司 |
| GICS 板塊/行業 | 健康護理(XLV)/生命科學工具與服務 |
| 標普500排名(按權重) | #75 · 0.24%(Oct 29, 2026) |
| 板塊內排名 | 健康護理 #11(Oct 29, 2026) |
| 總部 | 華盛頓特區 |
| 成立 | 1984 年 |
| 執行長 | 雷納·M·布萊爾 |
| 員工 | 約 63,000 人(2024 年 12 月 31 日) |
| 市值 | $166.59B(Oct 30, 2026) |
| 股價 | $232.23(Oct 30, 2026 收盤) |
| SEC 申報 | EDGAR — CIK 0000313616 |
業務概覽
丹納赫銷售用於發現、開發與製造藥物的生命科學工具、診斷與生物工藝產品。
其生物技術分部(包括 Cytiva)供應生物製造商所需的過濾器、樹脂與系統。
診斷業務(包括 Beckman Coulter 與 Cepheid)服務醫院與實驗室。
業務板塊
| 生物技術 | 藥物製造的生物工藝產品,包括 Cytiva。 2024 財年收入 67.59 億美元;營業利潤 16.85 億美元。 |
| 生命科學 | 研究實驗室的儀器與耗材。 2024 財年收入 73.29 億美元;營業利潤 8.79 億美元。 |
| 診斷 | 臨床診斷,包括 Beckman Coulter 與 Cepheid。 2024 財年收入 97.87 億美元;營業利潤 26.25 億美元。 |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1984 年 | 史蒂文與米切爾·雷爾斯創立丹納赫。 |
| 2016 年 | 丹納赫分拆工業業務為 Fortive。 |
| 2020 年 | 丹納赫收購 Cytiva。 |
| 2023 年 | 丹納赫分拆環境與應用解決方案業務為 Veralto。 |
競爭地位
財務快照
| 總收入 | $24.57B(FY2025 銷售額) |
| 營業利潤 | $4.69B(FY2025 營業利潤) |
| 淨利潤 | $3.61B(FY2025 淨利潤) |
| 稀釋 EPS | $5.05(FY2025 持續經營攤薄每股收益) |
主要風險
對標普500的重要性
丹納赫是藥物開發的「賣鏟人」:它銷售每家生物製造商都需要的工具,並以丹納赫業務系統推動利潤。風險在於生物科技融資週期,它會波動最高利潤生物工藝產品的需求。
來源與方法
| 財務、板塊、總部 | 丹納赫 2024 年報/Form 10-K(銷售額 238.8 億美元;營業利潤 48.6 億美元;淨利潤 39.0 億美元;持續經營攤薄每股收益 5.29 美元)。 |
| 指數權重與排名 | Slickcharts S&P 500 權重,Oct 29, 2026 收盤,Oct 30, 2026 抓取 |
| 市值 | $166.59B(Oct 30, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-30 05:26 · updated 2026-11-14 23:18 · rev 9